Valuation: Atossa Therapeutics, Inc.

Market Cap 20.32M 17.78M 16.39M 15.17M 28.79M 1.94B 29.27M 196M 76.96M 953M 76.29M 74.64M 3.3B P/E 2026 *
-0.54x
P/E 2027 * -0.68x
Enterprise Value 20.32M 17.78M 16.39M 15.17M 28.79M 1.94B 29.27M 196M 76.96M 953M 76.29M 74.64M 3.3B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-3.67%
1 week+11.32%
Current month+22.28%
1 month-46.49%
3 months-52.61%
6 months-75.61%
Current year-73.33%
1 week 2.14
Extreme 2.14
2.6
1 month 1.7
Extreme 1.7
2.81
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
107.25
10 years 1.7
Extreme 1.7
810
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
05-12
Ensisheim Partners LLC
OtherCompany 0 0%
05-12Free

Director

10,000 0.1161%
05-12Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-3.67%+11.32%-82.52%-86.78% 20.32M
+1.01%+2.79%+3.65%+11.65% 50.44B
+0.72%+1.00%+396.18%+624.25% 40.63B
+2.54%+0.93%+28.98%-3.62% 34.88B
+0.31%+1.74%+18.44%+59.76% 33.67B
-2.09%-1.98%+3.21%+33.56% 26.29B
-0.63%+0.34% - - 17.11B
+0.66%-3.96%+66.85%+127.36% 15.29B
-23.90%-21.43%+50.06%+53.83% 10.62B
+1.28%+0.46%+14.95%+22.37% 13.74B
Average -2.38%-1.31%+55.53%+93.60% 24.27B
Weighted average by Cap. -0.47%-0.60%+87.58%+139.84%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.71M -30.17M -27.91M -52.98M -3.57B -53.86M -361M -142M -1.75B -140M -137M -6.07B -39.31M -34.39M -31.71M -29.34M -55.7M -3.75B -56.63M -380M -149M -1.84B -148M -144M -6.38B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
09/07/26 US$2.360 -3.67% 144,165
08/07/26 US$2.450 -1.61% 127,999
07/07/26 US$2.490 +9.21% 426,355
06/07/26 US$2.280 +7.55% 228,476
02/07/26 US$2.120 +3.92% 116,527
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.360USD
Average target price
22.00USD
Spread / Average Target
+832.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock